Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ferring And Blackstone Launch Gene Therapy Company

Set Up To Market Nadofaragene Firadenovec For Bladder Cancer

Executive Summary

The Swiss group has decided to launch FerGene with the private equity giant to give the gene therapy nadofaragene firadenovec, which has a priority review at the FDA, a better chance for a successful launch in the US.

You may also be interested in...



Pharma Veteran Sørensen To Help Guide Ferring's Growth Plans

After more than three decades being associated with Novo Nordisk, Lars Rebien Sørensen has signed up to be chairman of Ferring, telling Scrip that the privately owned Swiss group's philosophy chimes with his own.

Blackstone Emerges As Likely Buyer For Takeda's OTC Business At Price Close To $3Bn

Takeda's divestment long has been rumored and would take it to its oft-stated target of selling around $10bn in assets to pay down debt associated with its $62bn purchase of Shire that closed in January 2019.

Blackstone Emerges As Likely Buyer Of Takeda OTC Business

Private equity group Blackstone is reportedly near a deal to acquire Takeda's consumer health business in Japan for up to $2.8bn as the Japanese pharma firm continues to shed non-core assets.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141239

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel